FDA is­sues draft guid­ance on NASH drug de­vel­op­ment

The FDA on Mon­day is­sued draft guid­ance on de­vel­op­ing drugs to treat pa­tients who have non­cir­rhot­ic non­al­co­holic steato­hep­ati­tis (NASH) with liv­er fi­bro­sis.

“Cur­rent­ly, there are no ap­proved drugs for the treat­ment of NASH. Giv­en the high preva­lence of NASH, the as­so­ci­at­ed mor­bid­i­ty, the grow­ing bur­den of end-stage liv­er dis­ease, and the lim­it­ed avail­abil­i­ty of liv­ers for or­gan trans­plan­ta­tion, FDA be­lieves that iden­ti­fy­ing ther­a­pies that will slow the progress or, halt, or re­verse NASH and NAFLD will ad­dress an un­met med­ical need,” FDA writes.

How­ev­er, FDA ac­knowl­edges that there are knowl­edge gaps that present chal­lenges to de­vel­op­ing drugs to treat NASH. One par­tic­u­lar chal­lenge is that there are cur­rent­ly no cri­te­ria for iden­ti­fy­ing which pa­tients with non­al­co­holic fat­ty liv­er (NAFL) will progress to NASH.

Be­cause of this, FDA says that spon­sors should fo­cus on de­vel­op­ing treat­ments non­cir­rhot­ic NASH with liv­er fi­bro­sis un­til there are meth­ods for iden­ti­fy­ing the sub­set of pa­tients who are at risk of pro­gres­sion.

FDA al­so en­cour­ages spon­sors to de­vel­op and val­i­date bio­mark­ers for di­ag­nos­ing and grad­ing NASH and liv­er fi­bro­sis, as liv­er biop­sy is cur­rent­ly the on­ly re­li­able method for di­ag­nos­ing the dis­ease.


The guid­ance it­self pro­vides rec­om­men­da­tions for pre­clin­i­cal and clin­i­cal de­vel­op­ment as well as tri­al de­sign and end­point se­lec­tion to sup­port ap­proval of drugs to treat non­cir­rhot­ic NASH with liv­er fi­bro­sis.

FDA notes that the guid­ance is not meant to cov­er the de­vel­op­ment of drugs to treat cir­rho­sis caused by NASH or the de­vel­op­ment of in vit­ro di­ag­nos­tics that may be used in de­vel­op­ing drugs to treat the dis­ease.

For Phase 3 stud­ies, FDA says that spon­sors should en­roll pa­tients with a his­to­log­i­cal di­ag­no­sis of NASH with liv­er fi­bro­sis made with­in six months of en­roll­ment, tak­ing in­to con­sid­er­a­tion pa­tients’ stan­dard of care and back­ground ther­a­py for oth­er chron­ic con­di­tions. FDA al­so says that pa­tients’ weight should be sta­ble for three months pri­or to en­roll­ment.

FDA al­so says that Phase 3 stud­ies for NASH should be dou­ble-blind and place­bo-con­trolled with the goal of slow­ing, halt­ing or re­vers­ing dis­ease pro­gres­sion and im­prov­ing clin­i­cal out­comes.

“Be­cause of the slow pro­gres­sion of NASH and the time re­quired to con­duct a tri­al that would eval­u­ate clin­i­cal end­points such as pro­gres­sion to cir­rho­sis or sur­vival, the FDA rec­om­mends spon­sors con­sid­er … liv­er his­to­log­i­cal im­prove­ments as end­points rea­son­ably like­ly to pre­dict clin­i­cal ben­e­fit to sup­port ac­cel­er­at­ed ap­proval,” FDA writes.

Those end­points in­clude res­o­lu­tion of steato­hep­ati­tis on over­all histopatho­log­i­cal read­ing and no wors­en­ing of liv­er fi­bro­sis on NASH Clin­i­cal Re­search Net­work (CRN) fi­bro­sis score and/or im­prove­ment in liv­er fi­bro­sis greater than or equal to one stage (NASH CRN fi­bro­sis score) and no wors­en­ing of steato­hep­ati­tis.

For NASH treat­ments grant­ed ac­cel­er­at­ed ap­proval on the ba­sis of liv­er his­tol­ogy, FDA says that ran­dom­ized, dou­ble-blind, place­bo-con­trolled tri­als to ver­i­fy clin­i­cal ben­e­fits should be un­der­way when the mar­ket­ing ap­pli­ca­tion is sub­mit­ted.

The guid­ance al­so pro­vides some caveats for pe­di­atric de­vel­op­ment, as “Pe­di­atric NASH ap­pears to have dif­fer­ent his­to­log­i­cal char­ac­ter­is­tics as well as a dif­fer­ent nat­ur­al his­to­ry when com­pared to adult NASH. For rea­sons that are cur­rent­ly un­known, dis­ease char­ac­ter­is­tics and pro­gres­sion in pe­di­atric pa­tients may be dif­fer­ent.”

As such, FDA says that ex­trap­o­la­tion of ef­fi­ca­cy from adults “is not ap­pro­pri­ate at this time,” and that lon­gi­tu­di­nal nat­ur­al his­to­ry da­ta for pe­di­atric pa­tients are need­ed.

FDA says it plans to fur­ther ad­dress is­sues re­lat­ed to pe­di­atric non­cir­rhot­ic NASH in an up­com­ing guid­ance.

Draft Guid­ance, Fed­er­al Reg­is­ter No­tice

First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Com­mu­ni­cat­ing the val­ue of pre­ci­sion med­i­cine

By Natasha Cowan, Content Marketing Manager at Blue Latitude Health.
Many stakeholders are confused by novel precision medicines, including patients and healthcare professionals. So, how can industry help them to navigate this complexity?

Precision medicine represents a new paradigm in healthcare. It embodies the shift from treating many patients with the same therapy, to having the tools to identify the best treatment for every patient.

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

What differentiates a woman leader in biopharma R&D from a man?

Not much, except there are fewer of them in senior posts. Data suggest women are not more risk-averse, family-oriented or less confident than their male counterparts — indeed the differences between the two sexes are negligible. But a glance at the top R&D positions in Big Pharma leaves little doubt that upward migration in the executive ranks of biopharma R&D is tough.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 64,800+ biopharma pros reading Endpoints daily — and it's free.

The lat­est Cin­derel­la sto­ry in on­col­o­gy ends with a sud­den rout as up­dat­ed da­ta dis­play spooks in­vestors

NextCure’s turn as the Cinderella of cancer-focused biotechs was short-lived.
Just a few days after its shares $NXTC zoomed up more than 250% on some very early stage results in a SITC abstract, a more complete analysis over the weekend spiked the hype and left investors in high dudgeon as the stock price collapsed back towards earth Monday.
The focus at NextCure is centered on NC318, an antibody that is intended to shut down the immunosuppressive Siglec-15 — or S-15 — target. After adding a small group of patients to the readout, investigators circled 2 clinical responses, a complete and partial response, along with 4 stable disease cases in non-small cell lung cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 64,800+ biopharma pros reading Endpoints daily — and it's free.

Te­va spin­out rais­es $85M in IPO; No­var­tis beefs up gener­ics unit with $440M deal

→ After Teva spinout 89bio recently announced that its IPO was being held up, the company is back in the game offering 5,304,687 shares at a price of $16 per share. The company has raised $84.9 million IPO in gross proceeds and will be listed under the ticker symbol $ETNB. BofA Securities, SVB Leerink and RBC Capital Markets are the joint book-running managers for the offering. Oppenheimer & Co is the co-manager for the offering.
→ Looking to amp up its presence in Japan’s hospitals, Novartis has struck a deal to buy out Aspen’s portfolio of generics in the world’s third largest healthcare market. The pharma giant is paying $440 million for Aspen’s Japanese subsidiary.
→ Novartis said tropifexor, a non-bile acid FXR agonist, has scored on several key biomarkers of NASH in a Phase IIb trial, including reductions in hepatic fat, alanine aminotransferase and body weight compared to a placebo at 12 weeks.

Break­through sta­tus and promise of a speedy re­view ar­rives for Op­di­vo/Yer­voy com­bi­na­tion as Bris­tol-My­ers bites at Bay­er

Its frontline and single-agent aspirations have been set back, but Bristol-Myers Squibb just took a big step forward in its efforts to apply its checkpoint inhibitor Opdivo to liver cancer. The FDA has granted breakthrough status and priority review to a combination, second-line treatment.

The designation is for Opdivo (nivolumab) in combination with Yervoy (ipilimumab),  for treating advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. The PD-L1 drug was already approved as a single-agent, second-line treatment for HCC. A PDUFA date was set for March 10, 2020 — just 4 months from now.

Third time un­lucky: Lipocine's lat­est quest to mar­ket their oral testos­terone drug snubbed again by FDA

Lipocine’s latest attempt at securing approval for its oral testosterone drug has fizzled yet again.

The Utah-based drug developer on Monday said the FDA has spurned its marketing application, indicating that some efficacy data on the drug, Tlando, was not up to scratch to treat male hypogonadism, a condition characterized by low production of the hormone testosterone, which is responsible for maintaining muscle bulk, bone growth, and sexual function.

UP­DAT­ED: De­cry­ing 'ar­bi­trary and capri­cious' ac­tion, Re­genxBio sues FDA over clin­i­cal holds on gene ther­a­py

When RegenxBio disclosed that the FDA had placed a partial clinical hold on one of its lead gene therapies, execs outlined several customary next steps: continuing assessment and monitoring, delaying a related IND filing, and working with the FDA to address the matter.

As it turned out, they were planning something much less mundane. Two days after announcing the hold in its Q3 update, RegenxBio filed a lawsuit seeking to set it aside, the FDA Law Blog noted.

Roche's SMA chal­lenge to Bio­gen's Spin­raza fran­chise looms larg­er with piv­otal win

Roche has just landed a crucial advance in scoring a come-from-behind win on the spinal muscular atrophy field, giving Novartis and Biogen a run for their money.

The update was brief, but Roche said risdiplam hit the primary endpoint in the placebo-controlled pivotal SUNFISH trial, meeting the threshold for change from baseline in the Motor Function Measure 32 (MFM-32) scale after one year of treatment. The results, which is the second, confirmatory portion of a two-part study, involved 180 patients with type 2 or 3 spinal muscular atrophy between 2 and 25 years old.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 64,800+ biopharma pros reading Endpoints daily — and it's free.

Roche steers Gazy­va in­to a new PhI­II pro­gram af­ter com­bo shows promise in lu­pus nephri­tis study

Roche is working on putting together a late-stage study for its monoclonal antibody Gazyva in patients with severe kidney disease associated with lupus after a combination approach helped patients in a mid-stage study.

The 125-patient NOBILITY trial evaluated Gazyva, combined with standard-of-care treatment mycophenolate mofetil or mycophenolic acid and corticosteroids, versus standard treatment alone. The combo met the main goal of inducing a statistically superior complete renal response (CRR) of 40% at week 76, versus 18% in patients given standard treatment, Roche said.